Participated · Seed · Apr 2024

Atouch is a service that integrates a company’s LINE official account with automated responses, chatbots, payment processing and e-commerce capabilities to enable fast conversions and smoother customer interactions. The product emphasizes an intuitive management interface designed for easy setup and operation, aiming to make shop creation simple for a wide range of users. It supports 24/7 automated communication via chatbots and auto-response to improve customer satisfaction and speed up order flows. The platform is positioned as flexible and customizable to fit different industries and company sizes, with easy deployment and low operational overhead. IRIS Data Lab says it will use the recent funding to further improve service features, strengthen product quality and reinforce the company’s foundation. The company was founded on March 5, 2019 and is based in Minato-ku, Tokyo.

Participated · Series D · Jan 2024

PR Table provides talentbook, a one‑stop recruitment PR platform that plans recruitment strategy, creates content, distributes it, and accumulates engagement and action data to optimize digital PR for hiring. The company says it has served more than 1,200 enterprise and growth customers across industries. In the past year PR Table reports revenue roughly doubled and headcount expanded from 35 to 64 employees. It intends to invest the new proceeds into talentbook product development and its own hiring to strengthen organizational support for enterprise recruiting marketing. The firm was founded in 2014 and is based in Chiyoda, Tokyo. Cumulatively it has raised ¥1.7 billion (including capital‑type loans). PR Table rebuilt and rebranded its flagship corporate-branding SaaS from PR Table to talentbook, positioning the product as a company-focused talent directory that highlights employees. The service, launched in December 2015 by founders from Ozmapr and RareJob, is intended both for external employer branding and internal culture diffusion. Talentbook is described as a “new business card,” enabling users to surface employee backgrounds online to support post‑COVID business matching and introductions. The company has added features to diagnose reactions to published content and plans to support customer PDCA cycles to drive more effective culture‑penetration activities. User adoption has grown to just over 100 corporate customers (about 1,000 including free users). The firm says the talent‑focused positioning may lead to new SaaS launches, partnerships, or acquisitions to expand its corporate‑branding offering.

Participated · Series C · Aug 2022

Ubie, founded in 2017 and based in New York, offers the Ubie AI Symptom Checker, a medically vetted platform that guides users to appropriate care pathways using predictive models. The company supports over 1,800 provider organizations and leverages disease-prediction AI to help patients navigate healthcare systems. As of June 2025 Ubie has secured over $125 million in cumulative funding. The reported capital will be used to support U.S. expansion, develop generative AI for patient education, and continue refining provider-focused solutions in partnership with the Mayo Clinic. Investors named in the report include Google, JAPAN POST CAPITAL, NTT DOCOMO, SEVEN-ELEVEN JAPAN, Japan Finance Corporation and The Shoko Chukin Bank. Ubie is a healthtech company founded in May 2017 that builds AI-powered products to guide people to appropriate medical care. Its consumer offerings include the symptom search engine Ubie (Japanese and US versions) and Ubie Disease Q&A, together reaching about 10 million monthly users. For healthcare providers it offers Ubie AI Medical Navi, a digital intake and diagnosis-support tool adopted by more than 1,700 medical institutions since its 2018 launch. The company also operates matching businesses that connect consumers and medical providers and has collaborated with pharmaceutical firms, engaging with over two-thirds of global mega‑pharma since its pharma business launch in late 2021. Ubie established a U.S. office in 2022 as part of its international expansion. It plans to use recent funding to grow its pharma-facing business, enhance consumer service features, develop new businesses, and invest in system development and marketing for the Ubie platform. Ubie provides an AI-powered symptom checker app for consumers and a B2B hospital product called Ubie for Hospital (AI Monshin) that automates preliminary patient interviews. AI Monshin selects and asks around 20 questions from 3,500 question types using data extracted from about 50,000 medical research papers. More than 1,100 medical institutions in Japan use AI Monshin, and the consumer app has over 7 million monthly active users. The company employs approximately 200 people. Ubie launched its symptom checker in the U.S. earlier this year, opened a U.S. subsidiary in October, and entered Singapore in August as initial steps toward global expansion. It plans to scale its healthcare platform and ramp up U.S. penetration, while pursuing partnerships with pharmaceutical companies (many based on the U.S. East Coast). Ubie offers an AI-powered patient questionnaire that guides patients from symptoms to appropriate medical care and improves operational efficiency in the medical field. The company is led by CEO Yoshinori Abe. It is building a medical data platform to connect patients, medical institutions, and pharmaceutical companies. Ubie says the platform will help ensure patients visit the right medical institution at the right time and help physicians access relevant, up-to-date knowledge. The company also aims to help pharmaceutical companies provide patients with appropriate information and scientific findings related to their conditions. Ubie intends to use its recent funding to support business growth in Japan and the U.S.